Current therapeutics for spondyloarthritis

Bibliography

• Toussirot E, Wendling D. Current guidelines for the drug treatment of ankylosing spondylitis. Drugs 1998;56:225-40
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X. Treatment of ankylosing spondylitis and other spondyloarthritides. Curr Opin Rheumatol 2009;21:324-34
   PubMed Web of Science ®Google Scholar
• Goh L, Samanta A. A systematic medline analysis of therapeutic approaches in ankylosing spondylitis. Rheumatol Int 2009;29:1123-35
   PubMed Web of Science ®Google Scholar
• LaSalle SP, Deodhar AA. Appropriate management of axial spondyloarthritis. Curr Rheumatol Rep 2007;9:375-82
   PubMedGoogle Scholar
• Zochling J, Van der Heijde D, Burgos-Vargas R, ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006;65:442-52
   PubMed Web of Science ®Google Scholar
• Sidiropoulos PI, Hatemi G, Song IH, Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3 E initiative in rheumatology involving a broad panel of experts and practicing rheumatologists. Rheumatology 2008;47:355-61
   PubMed Web of Science ®Google Scholar
• Lavie F, Pavy S, Dernis E, Pharmacotherapy (excluding biotherapies) for ankylosing spondylitis: development of recommendations for clinical practice based on published evidence and expert opinion. Joint Bone Spine 2007;74:346-52
   PubMed Web of Science ®Google Scholar
• Haute Autorite de Sante. Diagnostic, prise en charge therapeutique et suivi des spondylarthrites. December 2008. Available from: www.has.fr
   Google Scholar
• Van den Bosch F. A survey of European and Canadian rheumatologists regarding the treatment of patients with ankyloisng spondylitis and extraarticular manifestations. Clin Rheumatol 2010;29:281-8
   PubMed Web of Science ®Google Scholar
• Amor B, Dougados M, Mijiyama M. Criteria of the classification of spondylarthropathies. Rev Rheum 1990;57:85-9
   PubMedGoogle Scholar
• Boulos P, Dougados M, Macleod SM, Pharmacological treatment of ankylosing spondylitis: a systematic review. Drugs 2005;65:2111-27
   PubMed Web of Science ®Google Scholar
• Song IH, Poddubnyy DA, Rudwaleit M, Benefits and risks of ankylosing spondylitis treatment with non steroidal antiinflammatory drugs. Arthritis Rheum 2008;58:929-38
   PubMed Web of Science ®Google Scholar
• Dougados M, Behier JM, Jolchine I, Efficacy of celecoxib, a cyclooxygenase-2 specific inhibitor, in the treatment of ankylosing spondylitis: a six week controlled study with comparison against placebo and against a conventional non steroidal antiinflammatory drug. Arthritis Rheum 2001;44:180-5
   PubMed Web of Science ®Google Scholar
• Van der Heijde D, Baraf HS, Ramos-Remus C, Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum 2005;52:1205-15
   PubMed Web of Science ®Google Scholar
• Anderson JJ, Baron G, Van der Heijde D, Ankylosing spondylitis assessment group preliminary definition improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876-86
   PubMed Web of Science ®Google Scholar
• Kautmann HJ, Taubin HL. Non steroidal antiinflammatory drugs activate quiescent inflammatory bowel disease. Ann Intern Med 1987;107:513-16
   PubMed Web of Science ®Google Scholar
• Jarrett SJ, Sivera F, Cawkwell LS, Clinical and MRI findings in ankylosing spondylitis patients eligible for antiTNFa therapy: response to short term etoricoxib therapy. Ann Rheum Dis 2009;68:1466-9
   PubMed Web of Science ®Google Scholar
• Wanders A, van der Heijde D, Landewe R, Non steroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis. Arthritis Rheum 2005;52:1756-65
   PubMed Web of Science ®Google Scholar
• Maugars Y, Mathis C, Berthelot JM, Assessment of the efficacy of sacroiliac corticosteroid injections in spondylarthropathies: a double blind study. Br J Rheumatol 1996;35:767-70
   PubMedGoogle Scholar
• Ferraz MB, Tugwell P, Goldsmith CH, Meta analysis of sulfasalazine in ankylosing spondylitis. J Rheumatol 1990;17:1482-6
   PubMed Web of Science ®Google Scholar
• Chen J, Liu C. Is sulfasalazine effective in ankylosing spondylitis? A systematic review of randomized controlled trials. J Rheumatol 2006;33:722-31
   PubMed Web of Science ®Google Scholar
• Braun J, Zochling J, Baraliakos X, Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomized controlled trial. Ann Rheum Dis 2006;65:1147-53
   PubMed Web of Science ®Google Scholar
• Gonzalez-Lopez L, Garcia-Gonzalez A, Vazquez-Del-Mercado M, Efficacy of methotrexate in ankylosing spondylitis: a randomized double blind placebo controlled trial. J Rheumatol 2004;31:1568-74
   PubMed Web of Science ®Google Scholar
• Chen J, Liu C, Lin J. Methotrexate for ankyloisng spondylitis. Cochrane Database Syst Rev 2006;4:CD004524
   Google Scholar
• van Denderen JC, van der Paardt M, Nurmohamed MT, Double blind, randomized, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis. Ann Rheum Dis 2005;64:1761-4
   PubMed Web of Science ®Google Scholar
• Braun J, Brandt J, Listing J, Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-93
   PubMed Web of Science ®Google Scholar
• Davis JC, van der Heijde D, Braun J, Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum 2003;48:323-6
   Google Scholar
• Van der Heijde D, Kivitz A, Schiff MH, Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo controlled trial. Arthritis Rheum 2006;54:2136-46
   PubMed Web of Science ®Google Scholar
• Heldmann F, Dybowski F, Sarachasi-Zender E, Update on biological therapy in the management of axial spondyloarthritis. Curr Rheumatol Rep 2010;12:325-31
   PubMedGoogle Scholar
• Dougados M, Combe B, Braun J. A randomized multicentre, double blind, placebo controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the Heel trial. Ann Rheum Dis 2010;69:1430-5
   PubMed Web of Science ®Google Scholar
• Dougados M, Braun J, Szanto S, Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomized, double blind, placebo controlled study (SPINE). Ann Rheum Dis 2011;70:799-804
   PubMed Web of Science ®Google Scholar
• Pham T, Fautrel B, Dernis E, Recommendations of the french society for rheumatology regarding TNF-alpha antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis. Joint Bone Spine 2007;74:638-46
   PubMed Web of Science ®Google Scholar
• Braun J, Davis J, Dougados M, First update of the international ASAS consensus statement for the use of anti-TNF-alpha agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:316-20
   PubMed Web of Science ®Google Scholar
• Breban M, Ravaud P, Claudepierre P, Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum 2008;58:88-97
   PubMed Web of Science ®Google Scholar
• Coates LC, Cawkwell LS, Ng NW, Real life experience confirms sustained response to long term biologics and switching in ankylosing spondylitis. Rheumatology 2008;47:897-900
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, Listing J, Brandt J, Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 2004;63:665-70
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, Schwarzlose S, Hilgert ES, MRI in predicting a major clinical response to anti tumor necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis 2008;67:1276-81
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Katz S, Etanercept for active Crohn's disease: a randomized double blind, placebo-controlled trial. Gastroenterology 2001;121:1088-94
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X, Listing J, Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti TNF agents infliximab and etanercept. Arthritis Rheum 2005;52:2447-51
   PubMed Web of Science ®Google Scholar
• Heiberg MS, Koldingsnes W, Mikklelsen K, The comparative one year performance of anti tumour necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from a longitudinal, observational, multicentre study. Arthritis Rheum 2008;59:234-40
   PubMed Web of Science ®Google Scholar
• Zochling J, Baraliakos X, Hermann KG, Magnetic resonance imaging in ankylosing spondylitis. Curr Opin Rheumatol 2007;19:346-52
   PubMed Web of Science ®Google Scholar
• Van der Heijde D, Landewe R, Baraliakos X, Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008;58:3063-70
   PubMed Web of Science ®Google Scholar
• Van der Heijde D, Landewe R, Einstein S, Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008;58:1324-31
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Salonen D, Weisman BN, Assessment of radiographic progression in the spine of patients with ankylosing spondylitis treated with adalimumab for up to two years. Arthritis Res Ther 2009;11(16): R127
   Google Scholar
• Baraliakos X, Listing J, Rudwaleit M, Impact of anti TNF therapy on erosive structural changes in the spine of patients with anlylosing spondylitis [abstract]. Ann Rheum Dis 2010;69(Suppl 3):432
   Google Scholar
• Barlow JH, Barefoot J. Group education for people with arthritis. Patient Educ Couns 1996;27:257-67
   PubMed Web of Science ®Google Scholar
• Dagfinrud H, Kvien TK, Hagen KB. Physiotherapy interventions for ankylosing spondylitis. Cochrane Database Syst Rev 2008;1:CD002822
   Google Scholar
• Sieper J. Can structural damage be prevented in ankylosing spondylitis. Curr Opin Rheumatol 2009;21:335-9
   PubMed Web of Science ®Google Scholar
• Daoussis D, Liossis SN, Solomou EE, Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. Arthritis Rheum 2010;62:150-8
   PubMed Web of Science ®Google Scholar
• Appel H, Ruiz-Heiland G, Listing J, Altered expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum 2009;60:3257-62
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, van der Heijde D, Landewe R, The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009;68:777-83
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, van der Heijde DM, Landewe R, The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2010;70:25-31
   PubMed Web of Science ®Google Scholar
• Haibel H, Rudwaleit M, Listing J, Efficacy of adalimumab in the treatment of axial spondyloarthritis without radiographically defined sacroiliitis. Results of a twelve- week randomized, double blind, placebo-controlled trial followed by an open label extension up to fifty-two. Arthritis Rheum 2008;58:1981-91
   PubMed Web of Science ®Google Scholar
• Barkham N, Keen HI, Coates LC, Clinical and imaging efficacy of infliximab in HLA-B27 positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum 2009;60:946-54
   PubMed Web of Science ®Google Scholar
• Tan AL, Marzo-Ortega H, O'Connor P, Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann Rheum Dis 2004;63:1041-5
   PubMed Web of Science ®Google Scholar
• Toussirot E, Wendling D. Antiinflammatory treatment with bisphosphonates in ankylosing spondylitis. Curr Opin Rheumatol 2007;19:340-5
   PubMed Web of Science ®Google Scholar
• Song IH, Heldmann F, Rudwaleit M, Different response to rituximab in tumor necrosis factor blocking naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed. A twenty four week clinical trial. Arthritis Rheum 2010;62:1290-7
   PubMed Web of Science ®Google Scholar
• Toussirot E, Saas P, Pouthier F, Increased production of soluble CTLA-4 in patients with spondylarthropathies correlates with disease activity. Arthritis Res Ther 2009;11(4): R101
   PubMed Web of Science ®Google Scholar
• Song I, Heldmann F, Rudwaleit M, Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum 2010;62:1290-7
   PubMed Web of Science ®Google Scholar
• Brulhart L, Nisen MJ, Chevallier P, Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists. Joint Bone Spine 2010;77:625-6
   PubMed Web of Science ®Google Scholar
• Tanaka T, Kuwahara Y, Shima M, Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody tocilizumab. Arthritis Rheum 2009;61:1762-4
   PubMed Web of Science ®Google Scholar
• Baeten D, Sieper J, Emery P, Secukinumab (anti IL-17) in the treatment of active ankylosing spondylitis [abstract]. Am Coll Rheumatol 2010;60:L7
   Google Scholar
• Braun J, van den Berg R, Baraliakos X, Eular 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011;70:896-904
   PubMed Web of Science ®Google Scholar